文献速递消化道肿瘤与早癌消化内镜

基于既往粪便血红蛋白浓度的结直肠癌粪便免疫化学检测筛查的危害-获益比

Harm-to-Benefit Ratio of Fecal Immunochemical Test-Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-10-11

该研究纳入荷兰结直肠癌筛查项目中完成至少2轮粪便免疫化学检测(FIT)的参与者,按既往粪便血红蛋白(f-Hb)浓度计算检出1例结直肠癌或进展期肿瘤所需筛查人数(NNS)和所需内镜人数(NNSc)。既往FIT阴性且未检出f-Hb者检出1例进展期肿瘤的NNS约为可检出f-Hb者的9倍(OR 8.71,95%CI 8.51-8.92),NNSc差异较小(OR 2.7,95%CI 2.7-2.8);作者认为对该低风险组可考虑降低筛查强度。

要点

  • 既往FIT阴性且未检出f-Hb者检出1例进展期肿瘤的NNS约为可检出f-Hb者的9倍(OR 8.71)。
  • NNSc在无既往可检出f-Hb者中亦较高,但差异较小(OR 2.7)。
  • 作者认为对无既往可检出f-Hb的低风险组可考虑降低筛查强度。

核心结论

  • 基于FIT的筛查在既往无可检出f-Hb者中的危害-获益比明显高于既往有可检出f-Hb者。
  • 作者认为对这一低风险组可考虑降低筛查强度。

研究设计与样本

  • 研究纳入荷兰结直肠癌筛查项目中完成最多4轮FIT筛查的参与者。
  • 共2,428,883名参与者完成至少2次连续FIT,1,308,684名完成3次FIT,150,958名完成4次FIT。
  • 主要结局为第2、3或4轮筛查中检出1例结直肠癌和/或进展期肿瘤的NNS与NNSc,并按既往f-Hb浓度分层。
  • 结局比较采用卡方检验和逻辑回归。

主要发现

  • 第2、3、4轮筛查分别检出31,400例、16,060例和2007例进展期肿瘤。
  • 无论筛查轮次,有既往可检出f-Hb史者与无既往可检出f-Hb史者的NNS差异均显著。
  • 既往FIT阴性且未检出f-Hb者检出1例进展期肿瘤的NNS约为可检出f-Hb者的9倍(OR 8.71,95%CI 8.51-8.92)。
  • NNSc呈现类似方向性模式,但差异较小(OR 2.7,95%CI 2.7-2.8)。

临床怎么用

  • 作者认为对既往FIT阴性且未检出f-Hb的低风险组可考虑降低筛查强度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This study aimed to provide evidence on the harm-to-benefit ratio of fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening by previous fecal hemoglobin (f-Hb) concentrations, as reflected in the number needed to screen (NNS) and number needed to scope (NNSc). METHODS: Participants in up to 4 FIT screening rounds of the Dutch CRC screening program were included. The main outcomes of this study were the NNS and NNSc to detect 1 CRC and/or advanced neoplasia (AN) in screening rounds 2, 3, or 4, conditional on previous f-Hb concentrations. Outcomes were compared between participants using chi-square tests and logistic regression. RESULTS: In total, 2,428,883 study participants completed at least 2 consecutive FITs, 1,308,684 completed 3 FITs, and 150,958 completed 4 FITs. There were 31,400, 16,060, and 2007 ANs detected by round, respectively. The NNS for individuals with vs without a history of detectable f-Hb differed significantly irrespective of screening round. Individuals without detectable f-Hb in previous negative FITs had almost 9 times the NNS to detect 1 AN compared with those with detectable f-Hb (odds ratio, 8.71; 95% confidence interval, 8.51-8.92). A similar directional pattern was observed for NNSc, although the differences were smaller (odds ratio, 2.7; 95% confidence interval, 2.7-2.8). CONCLUSIONS: The harm-to-benefit ratio of FIT-based screening is substantially greater in individuals without vs with prior detectable f-Hb. Less intensive screening should be considered for this lower-risk group.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Toes-Zoutendijk E, van de Schootbrugge-Vandermeer HJ, Katsara MA, et al. Harm-to-Benefit Ratio of Fecal Immunochemical Test-Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations. Clin Gastroenterol Hepatol. 2024. PMID: 39395573. doi:10.1016/j.cgh.2024.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。